OA02.03 Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study
2024; Elsevier BV; Volume: 19; Issue: 10 Linguagem: Inglês
10.1016/j.jtho.2024.09.026
ISSN1556-1380
AutoresS. Gadgeel, B.C. Cho, S. Lu, E. Felip, Hidetoshi Hayashi, A.I. Spira, B. Besse, Michael Thomas, Scott Owen, Yoon Jun Kim, S.-H. Lee, Josiane Mourão Dias, Y.-G. Lee, Yong Zhao, Yun Fang, N. Girard, Zhen Liu, Ping Sun, S.C. Sousa Oliveira, Hong Shen, L. Paz-Ares, Shingo Matsumoto, Haruo Tanaka, A.R. Ahmad, Т. Андабеков, P. Sunpaweravong, Özgür Özyılkan, J.C.-H. Yang, Maya Gottfried, Olga Susana Suárez Hernández, M. Kimmich, D. Cortinovis, D.L. Kaen, Lizbett Vanessa Garcia Montes, Sanjay Popat, Tom Newsom‐Davis, Juanjuan Xie, Tao Sun, E. Fennema, M. Daksh, Marguerite Ennis, Seema Sethi, Joshua Bauml, Dinh Chuong Nguyen,
Tópico(s)Gastric Cancer Management and Outcomes
Referência(s)